From: Protein arginine methylation: an emerging regulator of the cell cycle
Protein | Interacting PRMT | Known methylated residues | Result of methylation or PRMT interaction | Refs. |
---|---|---|---|---|
BGT2 | PRMT1 | – | BGT2 regulates PRMT1 activity in pre-B cells | [103] |
CDK4 | PRMT1 | R55, R73, R82, R163 | Destabilization of CDK4-cyclin D3 complex leading to pre-B cell differentiation | [103] |
PRMT5 | – | Interaction of CDK4 and PRMT5 regulates pRb/E2F-mediated transcription | [119] | |
Cyclin D1 | PRMT2 | – | Knockdown of PRMT2 correlates with increased cyclin D1 | [111] |
PRMT5 | – | Increased nuclear PRMT5 correlates with increased cyclin D1 protein levels | [121] | |
E2F1 | PRMT1 | R109 | Assists E2F1-dependent apoptosis during DNA damage | |
PRMT4 | – | Regulates E2F expression | [113] | |
PRMT5 | R111, R113 | Promotes cell proliferation | ||
Fanca | PRMT5 | – | Regulation of PRMT5-mediated methylation of p53 | [131] |
p16 | PRMT1 | R138 | Regulates p16 and CDK4 interaction to regulate cell proliferation | [107] |
PRMT5 | – | Increased nuclear PRMT5 negatively correlates with p16 protein expression and is associated with poor survival | [121] | |
PRMT6 | R22, R131, R138 | Methylation of p16 reduces binding of p16 with CDK4 | [136] | |
p21 | PRMT2 | – | Knockdown of PRMT2 correlates with increased p21 expression | [110] |
PRMT6 | – | Inhibition allowing cell cycle progression | [132] | |
R156 | Increased cytoplasmic localisation of p21, resulting in resistance to doxorubicin | [135] | ||
p27 | PRMT6 | – | Inhibition allowing cell cycle progression | [132] |
p53 | PRMT5 | R333, R335, R337 | Affects promoter specificity of p53 and enhances p53-dependent cell cycle arrest | [127] |
Unknown | R213 | Mediates p21 activation for cell cycle progression | [129] | |
pRb | PRMT2 | – | Repression of E2F transcriptional activity and cell cycle progression by binding to pRb | [108] |
PRMT4 | R775, R787, R798 | Decreases binding of pRb to E2F-1 leading to increased cell proliferation | [109] |